Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling

Proteome Science

Volumn 7, Issue , 2009, Pages 34-

  Voortman, Johannes ^a,b   Pham, Thang V ^a   Knol, Jaco C ^a   Giaccone, Giuseppe ^a,b   Jimenez, Connie R ^a  

^a Cancer Center   (Netherlands)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 13A; BORTEZOMIB; BRADYKININ; CISPLATIN; COMPLEMENT COMPONENT C3BETA; COMPLEMENT COMPONENT C3F; FIBRINOPEPTIDE A; FIBRINOPEPTIDE B; GEMCITABINE; HEMOGLOBIN A; INTER ALPHA TRYPSIN INHIBITOR HEAVY CHAIN H4; PHOSPHOFIBRINOPEPTIDE A; SERUM ALBUMIN; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OVERALL SURVIVAL; PEPTIDE MAPPING; PEPTIDOMICS; PREDICTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; SUPPORT VECTOR MACHINE; TREATMENT OUTCOME;

EID: 70350113624     PISSN: None     EISSN: 14775956     Source Type: Journal    
DOI: 10.1186/1477-5956-7-34     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66. 10.3322/canjclin.57.1.43, 17237035.
2. Spira A, Ettinger DS. Multidisciplinary Management of Lung Cancer. N Engl J Med 2004, 350:379-392. 10.1056/NEJMra035536, 14736930.
3. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker SJ, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR, . American Society of Clinical Oncology American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003. J Clin Oncol 2004, 22:330-353. 10.1200/JCO.2004.09.053, 14691125.
4. Shepherd FA. Current paradigms in first-line treatment of non-small-cell lung cancer. Oncology (Williston Park) 2004, 18:13-20.
5. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, . Eastern Cooperative Oncology Group Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-8. 10.1056/NEJMoa011954, 11784875.
6. Lopez MF, Mikulskis A, Kuzdzal S, Bennett DA, Kelly J, Golenko E, DiCesare J, Denoyer E, Patton WF, Ediger R, Sapp L, Ziegert T, Lynch C, Kramer S, Whiteley GR, Wall MR, Mannion DP, Della Cioppa G, Rakitan JS, Wolfe GM. High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. Clin Chem 2005, 51:1946-1954. 10.1373/clinchem.2005.053090, 16081505.
7. Liotta LA, Petricoin EF. Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest 2006, 116:26-30. 10.1172/JCI27467, 1323272, 16395400.
8. Petricoin EF, Liotta LA. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol 2004, 15:24-30. 10.1016/j.copbio.2004.01.005, 15102462.
9. Villanueva J, Philip J, DeNoyer L, Tempst P. Data analysis of assorted serum peptidome profiles. Nat Protoc 2007, 2:588-602. 10.1038/nprot.2007.57, 17406620.
10. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003, 422:198-207. 10.1038/nature01511, 12634793.
11. Jimenez CR, El Filali Z, Knol JC, Hoekman K, Kruyt FA, Giaccone G, Smit AB, Li KW. Automated serum peptide profiling using novel magnetic C18 beads off-line coupled to MALDI-TOF-MS. Proteomics Clin Appl 2007, 1:598-604.
12. Voortman J, Smit EF, Honeywell R, Kuenen BC, Peters GJ, Velde H. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors. Clin Cancer Res 2007, 13:3642-51. 10.1158/1078-0432.CCR-07-0061, 17575229.
13. Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. J Clin Oncol 2003, 21:3909-3917. 10.1200/JCO.2003.03.195, 14581415.
14. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The Proteasome Inhibitor PS-341 in Cancer Therapy. Clin Cancer Res 1999, 5:2638-2645.
15. Mortenson MM, Schlieman MG, Virudachalam S, Bold RJ. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Chemother Pharmacol 2004, 54:343-353.
16. Davies AM, Lara PN, Mack PC, Gandara DR. Incorporating bortezomib into the treatment of lung cancer. Clin Cancer Res 2007, 13:4647-51.
17. Ludwig H, Khayat D, Giaccone G, Facon T. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 2005, 104:1794-807. 10.1002/cncr.21414, 16178003.
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. J Natl Cancer Inst 2000, 92:205-216. 10.1093/jnci/92.3.205, 10655437.
19. Villanueva J, Martorella AJ, Lawlor K, Philip J, Fleisher M, Robbins RJ, Tempst P. Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol Cell Proteomics 2006, 5:1840-52. 10.1074/mcp.M600229-MCP200, 16896061.
20. Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, Nishio M, Brahmer J, Spreafico A, Ludovini V, Massion PP, Dziadziuszko R, Schiller J, Grigorieva J, Tsypin M, Hunsucker SW, Caprioli R, Duncan MW, Hirsch FR, Bunn PA, Carbone DP. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 2007, 99:838-46. 10.1093/jnci/djk195, 17551144.
21. Smith FM, Gallagher WM, Fox E, Stephens RB, Rexhepaj E, Petricoin EF, Liotta L, Kennedy MJ, Reynolds JV. Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy. Ann Surg 2007, 245:259-266. 10.1097/01.sla.0000245577.68151.bd, 1876990, 17245180.
22. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006, 116:271-84. 10.1172/JCI26022, 1323259, 16395409.
23. Villanueva J, Nazarian A, Lawlor K, Yi SS, Robbins RJ, Tempst P. A sequence-specific exopeptidase activity test (SSEAT) for "functional" biomarker discovery. Mol Cell Proteomics 2008, 7:509-518.